Respicardia is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time.
Type
Private
HQ
Hopkins, US
Founded
2006
Size (employees)
20 (est)+12%
Respicardia was founded in 2006 and is headquartered in Hopkins, US
Report incorrect company information

Key People/Management at Respicardia

Bonnie Labosky

Bonnie Labosky

President and CEO
Tim Hauch

Tim Hauch

Chief Financial Officer
Robin Germany

Robin Germany

Chief Medical Officer
Todd Goblish

Todd Goblish

Vice President of Research and Development

Respicardia Office Locations

Respicardia has an office in Hopkins
Hopkins, US (HQ)
150 12400 Whitewater Dr
Show all (1)
Report incorrect company information

Respicardia Financials and Metrics

Summary Metrics

Founding Date

2006

Total Funding

$149.1 m

Latest funding size

$58.50 m

Time since last funding

2 months ago

Investors

Respicardia's latest funding round in December 2017 was reported to be $58.5 m. In total, Respicardia has raised $149.1 m
Report incorrect company information